Palvella Therapeutics (PVLA) announced the appointment of Vimal Patel, PharmD, as Senior Vice President of Medical Affairs. Prior to joining Palvella, Dr. Patel served as Dermatology Therapeutic Area Head, Medical Affairs at Incyte (INCY).
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Palvella Therapeutics initiated with an Outperform at Mizuho
- Palvella Therapeutics price target raised to $133 from $97 at TD Cowen
- Palvella Therapeutics granted FDA Fast Track Designation to QTORIN
- Palvella Therapeutics price target raised to $204 from $148 at Canaccord
- Buy Rating Affirmed for Palvella Therapeutics Following Promising Phase 2 TOIVA Trial Results